AGIOS PHARMACEUTICALS INC (AGIO) is a publicly traded company in the Unknown sector. Across all available filings, 39 corporate insiders have executed 1041 transactions totaling $360.5M, demonstrating a bullish sentiment with $8.5M in net insider flow. The most recent transaction on Jan 5, 2026 involved a transaction of 8,475 shares valued at $0.
No significant insider buying has been recorded for AGIO in the recent period.
No significant insider selling has been recorded for AGIO in the recent period.
Based on recent SEC filings, insider sentiment for AGIO is bullish with an Insider Alignment Score of 51/100 and a net flow of $8.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at AGIOS PHARMACEUTICALS INC (AGIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 39 insiders are actively trading AGIO stock, having executed 1041 transactions in the past 90 days. The most active insider is Corp /de/ Celgene (Executive), who has made 2 transactions totaling $87.9M.
Get notified when executives and directors at AGIO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Milanova Tsveta | Chief Commercial Officer | Option Exercise | 8,475 | $N/A | $0 | |
| Jan 5, 2026 | Milanova Tsveta | Chief Commercial Officer | Sale | 2,872 | $27.02 | $77.6K | |
| Jan 5, 2026 | Milanova Tsveta | Chief Commercial Officer | Option Exercise | 8,475 | $N/A | $0 | |
| Dec 30, 2025 | Jones Cecilia | Chief Financial Officer | Option Exercise | 6,000 | $N/A | $0 | C-Suite |
| Dec 30, 2025 | Jones Cecilia | Chief Financial Officer | Sale | 2,932 | $27.09 | $79.4K | C-Suite |
| Dec 30, 2025 | Jones Cecilia | Chief Financial Officer | Option Exercise | 6,000 | $N/A | $0 | C-Suite |
| Dec 30, 2025 | Milanova Tsveta | Chief Commercial Officer | Option Exercise | 6,000 | $N/A | $0 | |
| Dec 30, 2025 | Milanova Tsveta | Chief Commercial Officer | Sale | 2,932 | $27.09 | $79.4K | |
| Dec 30, 2025 | Milanova Tsveta | Chief Commercial Officer | Option Exercise | 6,000 | $N/A | $0 | |
| Dec 30, 2025 | Gheuens Sarah | Chief Medical Officer | Option Exercise | 6,000 | $N/A | $0 | |
| Dec 30, 2025 | Gheuens Sarah | Chief Medical Officer | Sale | 2,932 | $27.09 | $79.4K | |
| Dec 30, 2025 | Gheuens Sarah | Chief Medical Officer | Option Exercise | 6,000 | $N/A | $0 | |
| Dec 30, 2025 | William Burns James | Chief Legal Officer | Option Exercise | 6,000 | $N/A | $0 | |
| Dec 30, 2025 | William Burns James | Chief Legal Officer | Sale | 2,932 | $27.09 | $79.4K | |
| Dec 30, 2025 | William Burns James | Chief Legal Officer | Option Exercise | 6,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 9 | $184.5M | 47.5% |
Sale(S) | 513 | $176.0M | 45.3% |
Exercise(M) | 396 | $23.7M | 6.1% |
Payment(F) | 71 | $4.0M | 1.0% |
Award(A) | 1 | $10.6K | 0.0% |
Gift(G) | 16 | $0 | 0.0% |
Other(J) | 35 | $0 | 0.0% |
Insider activity at AGIOS PHARMACEUTICALS INC shows mixed signals across all time. While $184.5M in purchases indicates some executive confidence,$176.0M in sales balances the picture, resulting in a modest net flow of $8.5M.39 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Corp /de/ Celgene, has transacted $87.9M during this period.